A5051174375- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Clinical Nutrition and Gastroenterology
- Hemoglobinopathies and Related Disorders
- COVID-19 and healthcare impacts
- Multiple Myeloma Research and Treatments
- Cytomegalovirus and herpesvirus research
- Renal Transplantation Outcomes and Treatments
- Oral health in cancer treatment
- Nutrition and Health in Aging
- Complement system in diseases
- T-cell and Retrovirus Studies
- Polyomavirus and related diseases
- T-cell and B-cell Immunology
- Viral-associated cancers and disorders
- Blood disorders and treatments
The University of Queensland
2015-2024
Royal Brisbane and Women's Hospital
2015-2024
Queensland University of Technology
2022-2024
Mater Health Services
2020-2024
Queensland Health
2007-2023
Cancer Care Services
2006-2021
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
2021
University of Naples Federico II
2021
Agostino Gemelli University Polyclinic
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a devastating complication; the optimal prophylactic strategy remains unclear. We performed multicentre, retrospective analysis of patients with DLBCL high risk for CNS as defined by two or more of: multiple extranodal sites, elevated serum LDH and B symptoms involvement specific high-risk anatomical sites. compared three different strategies CNS-directed therapy: intrathecal (IT) methotrexate (MTX) (R)-CHOP...
Acute myeloid leukemia (AML) blasts express high levels of interlekin-3 (IL-3) receptor-α (CD123). CSL360 is a recombinant, chimeric immunoglobulin G1 (IgG1), anti-CD123 monoclonal antibody (MoAb) that neutralizes IL-3 and demonstrates anti-leukemic activity in vitro. This phase 1 study assessed safety, pharmacokinetics bioactivity weekly intravenous for 12 weeks 40 patients with advanced AML across five dose (0.1–10.0 mg/kg). Other than mild infusion reactions, was well tolerated. The...
Telomerase enables replicative immortality in most cancers including acute myeloid leukemia (AML). Imetelstat is a first-in-class telomerase inhibitor with clinical efficacy myelofibrosis and myelodysplastic syndromes. Here, we develop an AML patient-derived xenograft resource perform integrated genomics, transcriptomics lipidomics analyses combined functional genetics to identify key mediators of imetelstat efficacy. In randomized phase II-like preclinical trial xenografts, effectively...
Abstract: Objectives: Alemtuzumab (anti‐CD52, Campath‐1H) has recently been shown to be effective in the treatment of a range hematological malignancies, including B‐cell chronic lymphocytic leukemia and T‐cell prolymphocytic leukemia. We undertook phase II study evaluate safety, tolerability efficacy alemtuzumab patients with relapsed or refractory advanced stage cutaneous lymphoma. Patients methods: A total eight were enrolled, seven mycosis fungoides/Sézary syndrome (MF/SS) one large‐cell...
The reconstitution of anti-viral cellular immunity following hematopoietic stem cell transplantation (HSCT) is crucial in preventing cytomegalovirus (CMV)-associated complications. Thus immunological monitoring has emerged as an important tool to better target pre-emptive therapies. However, traditional laboratory-based assays are too cumbersome and complicated implement a clinical setting. Here we conducted prospective study new whole blood assay (referred QuantiFERON-CMV®) determine the...
Nutrition support is frequently required post-allogeneic haematopoietic progenitor cell transplantation (HPCT); however, the impact of mode feeding on gastrointestinal microbiome has not been explored. This study aimed to determine if there a difference in between patients receiving enteral nutrition (EN) and parenteral (PN) HPCT. Twenty-three received either early EN or PN when required. Stool samples were collected at 30 days post-transplant analysed with shotgun metagenomic sequencing....
Abstract Sorafenib maintenance improves outcomes after hematopoietic cell transplant (HCT) for patients with FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML). Although promising have been reported sorafenib plus intensive chemotherapy, randomized data are limited. This placebo-controlled, phase 2 study (ACTRN12611001112954) 102 (aged 18-65 years) 2:1 to vs placebo (days 4-10) combined induction: idarubicin 12 mg/m2 on days 1 3 either cytarabine...
Abstract Donor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate travel risks associated with COVID-19 pandemic. However, little is known regarding postthaw quality such allogeneic or effect precryopreservation storage processing on these characteristics. We investigated CD34+ recovery viability 305 HPC cryopreserved at 9 laboratories across...
Core binding factor acute myeloid leukemia (CBF AML), with t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22) and the associated fusion gene transcripts AML1/ETO CBFβ/MYH11, has a favourable clinical prognosis although significant numbers of patients still suffer relapse. We examined prognostic utility serial bone marrow minimal residual disease (MRD) monitoring by RQ-PCR in cohort CBF AML long term follow-up. Twenty-nine were evaluated median follow 34 months. Twelve relapses occurred...
Oral mucositis is a common complication during haematopoietic stem cell transplantation (HSCT). This study aimed to assess the incidence of severe in patients undergoing different HSCT regimens.This single-centre retrospective reviewed daily oral assessment for 467 consecutive who underwent transplant regimens matched unrelated or related allogeneic with post-transplant methotrexate, haploidentical mismatched cyclophosphamide (PTCy), autologous HSCT. care and cryotherapy melphalan were used....
Endothelial function and integrity are compromised after allogeneic bone marrow transplantation (BMT), but how this affects immune responses broadly remains unknown. Using a preclinical model of CMV reactivation BMT, we found antiviral humoral induced by IL-6 signaling. signaling in T cells maintained Th1 cells, resulting sustained IFN-γ secretion, which promoted endothelial cell (EC) injury, loss the neonatal Fc receptor (FcRn) responsible for IgG recycling, rapid loss. cell-specific...
Major ABO mismatch in hematopoietic progenitor cell transplantation (HPCT) is associated with a range of immunohematologic consequences including infusion (PCI)-related hemolysis, delayed red blood engraftment, and pure aplasia (PRCA). Although pretransplant (recipient) isoagglutinin reduction may be decreased complications this setting, there no consensus respect to strategies for reduction.This observational study assessed the efficacy standardized strategy incorporating donor-type...
Previous research at our institution (1988-1998) established an intensive care unit (ICU) and hospital mortality between 70% 80% in haemopoietic stem cell transplant (HSCT) patients requiring ICU admission.This study explored a more contemporary cohort while comparing outcomes to published literature previous experience.Retrospective chart review of HSCT admitted December 1998 June 2008.Of 146 admissions, 53% were male, with mean age 44 years, Acute Physiologic Chronic Health Evaluation II...
Patients receiving treatment for acute myeloid leukemia (AML) commonly experience life-threatening complications requiring intensive care unit (ICU) support. This is a retrospective study of 505 patients with newly diagnosed AML who were treated chemotherapy between January 1999 and December 2010. Eighty-three (16.4%) identified had required 92 ICU admissions. The indication admission was hemodynamic instability in 47.0% respiratory impairment 42.2%. underlying pathology most infection...
BACKGROUND: Objective diagnosis of transplantation‐associated thrombotic microangiopathy (TA‐TMA) has traditionally been difficult due to the multiple potential etiologies thrombocytopenia and red blood cell fragmentation occurring after allogeneic hematopoietic stem transplantation (SCT). To attempt address this issue diagnostic uncertainty, two new criteria for TA‐TMA have recently proposed: Bone Marrow Transplant Clinical Trials Network (BMT‐CTN) International Working Group (IWG)...
Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction protoporphyrin IX (PPIX), which can lead to progressive liver disease characterized by recurrent EPP crises and end‐stage disease. We used the Australian Transplant Registry identify 5 patients referred for transplantation between 2008 2017. A total 4 had secondary ferrochelatase deficiency, 1 patient X‐linked EPP. No follow‐up with a specialist prior diagnosis There were 3...
Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is an established complication in patients undergoing allogeneic hemopoietic stem cell transplantation (HSCT). Defibrotide effective and safe pharmacologic option for treating diagnosed SOS/VOD. By exploring data provided to the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) by centers Australia New Zealand, this study aimed describe incidence of SOS/VOD patterns defibrotide use from 2016 2020. Patients who...